Argenx Se’s Growth Potential Bolstered by Vyvgart Hytrulo Approval and Strategic Positioning

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on ARGX stock, giving a Buy rating on April 11.

Thomas Smith has given his Buy rating due to a combination of factors that highlight Argenx Se’s promising market position and potential for growth. The recent approval of the pre-filled syringe formulation of Vyvgart Hytrulo in the U.S. is a significant milestone, as it allows for patient self-administration without the need for clinician monitoring. This development is expected to enhance the drug’s uptake among patients with myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP), providing a competitive edge in the market.
Furthermore, the approval was timely, aligning with the PDUFA date, which alleviated investor concerns about possible delays due to FDA issues. The strategic pricing of the pre-filled syringe at a slight premium and its coverage under Medicare Part D are expected to positively impact the company’s financials. Additionally, Argenx Se is anticipated to benefit from upcoming clinical data releases over the next 12 to 18 months, which could further expand its product pipeline and solidify its leadership in the immunology sector.